课题基金 / 基金详情

NEUROBIOLOGY OF DISRUPTIVE BEHAVIOR DISORDERS

NEUROBIOLOGY OF DISRUPTIVE BEHAVIOR DISORDERS
破坏性行为障碍的神经生物学
批准号:
3921958
负责人:
J L RAPOPORT
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

J L RAPOPORT的其他基金

相似基金

相关文献

中文摘要
翻译
攻击行为维度之间的关系, 冲动性和单胺代谢物的浓度, 特别是5-HIAA,在儿童的脊髓液中, 正在检查儿童期的破坏性行为障碍。 作为 作为研究的一部分, 儿童研究正在得到澄清。 社会测量 环境变量正在进行评估, 家庭环境与节能措施的关系。 随访研究,以解决测量的预测效度 在儿童和青少年中进行CSF 5-HIAA的研究。 为了研究5-羟色胺在ADD病理生理学中的作用, 20例多动症患儿给予芬氟拉明(0.6- 2.0mg/kg), 双盲交叉研究中的苯丙胺或安慰剂。 芬氟拉明对行为没有任何影响。 然而,在这方面, 显著的生化变化(尿和血浆MHPG减少, 尿NE、E和VMA减少)。 中枢多巴胺能效应 从血浆催乳素增加推断, 血小板血清素 尽管其结构类似于 安非他明芬氟拉明实际上没有治疗作用 方面的影响.
英文摘要
The relationships between behavioral dimensions of aggression, impulsivity, and concentrations of monoamine metabolites, particularly 5-HIAA, in the spinal fluid of children with disruptive behavior disorders of childhood are being examined. As part of that investigation, methodologic variables in spinal fluid studies of children are being clarified. Measurement of socio- environmental variables is being carried out to assess the relations between family environment and serotonenergic measures. Follow-up study to address the predictive validity of measurement of CSF 5-HIAA in children and adolescents is underway. To investigate the role of serotonin in the pathophysiology of ADD, 20 hyperactive boys received fenfluramine (0.6-2.0 mg/kg), dextroamphetamine or placebo in a double-blind crossover study. Fenfluramine had no behavioral effect whatsoever. However, striking biochemical changes (decreased urinary and plasma MHPG, decreased urinary NE, E and VMA). Central serotonergic effects were inferred from the increased plasma prolactin and decreased platelet serotonin. In spite of its structural similarly to amphetamine, fenfluramine has virtually noen of its therapeutic effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DIAGNOSIS IN CHILD PSYCHIATRY
EVALUATION AND TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND RELATED DISORDERS
CHILDHOOD ONSET SCHIZOPHRENIA
BRAIN STRUCTURE AND FUNCTION IN DEVELOPMENTAL NEUROPSYCHOLOGICAL DISORDERS
海外基金